252 related articles for article (PubMed ID: 29759551)
1. Genomics and pharmacogenomics of pediatric acute lymphoblastic leukemia.
Wu C; Li W
Crit Rev Oncol Hematol; 2018 Jun; 126():100-111. PubMed ID: 29759551
[TBL] [Abstract][Full Text] [Related]
2. Genomic and pharmacogenetic studies of childhood acute lymphoblastic leukemia.
Pui CH
Front Med; 2015 Mar; 9(1):1-9. PubMed ID: 25511622
[TBL] [Abstract][Full Text] [Related]
3. IL-7 Receptor Mutations and Steroid Resistance in Pediatric T cell Acute Lymphoblastic Leukemia: A Genome Sequencing Study.
Li Y; Buijs-Gladdines JG; Canté-Barrett K; Stubbs AP; Vroegindeweij EM; Smits WK; van Marion R; Dinjens WN; Horstmann M; Kuiper RP; Buijsman RC; Zaman GJ; van der Spek PJ; Pieters R; Meijerink JP
PLoS Med; 2016 Dec; 13(12):e1002200. PubMed ID: 27997540
[TBL] [Abstract][Full Text] [Related]
4. Incidence and clinical outcome of children with BCR/ABL-positive acute lymphoblastic leukemia (ALL). A prospective RT-PCR study based on 673 patients enrolled in the German pediatric multicenter therapy trials ALL-BFM-90 and CoALL-05-92.
Schlieben S; Borkhardt A; Reinisch I; Ritterbach J; Janssen JW; Ratei R; Schrappe M; Repp R; Zimmermann M; Kabisch H; Janka-Schaub G; Bartram CR; Ludwig WD; Riehm H; Lampert F; Harbott J
Leukemia; 1996 Jun; 10(6):957-63. PubMed ID: 8667652
[TBL] [Abstract][Full Text] [Related]
5. Asparagine synthetase (ASNS) gene polymorphism is associated with the outcome of childhood acute lymphoblastic leukemia by affecting early response to treatment.
Pastorczak A; Fendler W; Zalewska-Szewczyk B; Górniak P; Lejman M; Trelińska J; Walenciak J; Kowalczyk J; Szczepanski T; Mlynarski W;
Leuk Res; 2014 Feb; 38(2):180-3. PubMed ID: 24268318
[TBL] [Abstract][Full Text] [Related]
6. Pharmacogenomics in acute lymphoblastic leukemia.
Lee SHR; Yang JJ
Best Pract Res Clin Haematol; 2017 Sep; 30(3):229-236. PubMed ID: 29050696
[TBL] [Abstract][Full Text] [Related]
7. Methylene tetrahydrofolate reductase gene polymorphism in Egyptian children with acute lymphoblastic leukemia.
Tantawy AA; El-Bostany EA; Adly AA; Abou El Asrar M; El-Ghouroury EA; Abdulghaffar EE
Blood Coagul Fibrinolysis; 2010 Jan; 21(1):28-34. PubMed ID: 19923983
[TBL] [Abstract][Full Text] [Related]
8. Hepatic sinusoidal obstruction syndrome during maintenance therapy of childhood acute lymphoblastic leukemia is associated with continuous asparaginase therapy and mercaptopurine metabolites.
Toksvang LN; De Pietri S; Nielsen SN; Nersting J; Albertsen BK; Wehner PS; Rosthøj S; Lähteenmäki PM; Nilsson D; Nystad TA; Grell K; Frandsen TL; Schmiegelow K
Pediatr Blood Cancer; 2017 Sep; 64(9):. PubMed ID: 28423235
[TBL] [Abstract][Full Text] [Related]
9. Pharmacogenomics in cancer treatment defining genetic bases for inter-individual differences in responses to chemotherapy.
Ansari M; Krajinovic M
Curr Opin Pediatr; 2007 Feb; 19(1):15-22. PubMed ID: 17224657
[TBL] [Abstract][Full Text] [Related]
10. Pharmacogenomics of pediatric acute lymphoblastic leukemia.
Meeker ND; Yang JJ; Schiffman JD
Expert Opin Pharmacother; 2010 Jul; 11(10):1621-32. PubMed ID: 20429672
[TBL] [Abstract][Full Text] [Related]
11. [Therapeutic strategies for childhood high-risk acute lymphoblastic leukemia].
Lu XT
Beijing Da Xue Xue Bao Yi Xue Ban; 2013 Apr; 45(2):327-32. PubMed ID: 23591360
[TBL] [Abstract][Full Text] [Related]
12. Pharmacogenomics in pediatric acute lymphoblastic leukemia: promises and limitations.
Al-Mahayri ZN; Patrinos GP; Ali BR
Pharmacogenomics; 2017 May; 18(7):687-699. PubMed ID: 28468529
[TBL] [Abstract][Full Text] [Related]
13. Protein expression of the glucocorticoid receptor in childhood acute lymphoblastic leukemia.
Lauten M; Cario G; Asgedom G; Welte K; Schrappe M
Haematologica; 2003 Nov; 88(11):1253-8. PubMed ID: 14607754
[TBL] [Abstract][Full Text] [Related]
14. Antimetabolite-based therapy in childhood T-cell acute lymphoblastic leukemia: a report of POG study 9296.
Winter SS; Holdsworth MT; Devidas M; Raisch DW; Chauvenet A; Ravindranath Y; Ducore JM; Amylon MD
Pediatr Blood Cancer; 2006 Feb; 46(2):179-86. PubMed ID: 16007607
[TBL] [Abstract][Full Text] [Related]
15. Dic(9;20)(p13;q11) in childhood acute lymphoblastic leukaemia is related to low cellular resistance to asparaginase, cytarabine and corticosteroids.
Lönnerholm G; Nordgren A; Frost BM; Jonsson OG; Kanerva J; Nygaard R; Schmiegelow K; Larsson R; Forestier E
Leukemia; 2009 Jan; 23(1):209-12. PubMed ID: 18615108
[No Abstract] [Full Text] [Related]
16. Prognostic impact of IKZF1 deletions in association with vincristine-dexamethasone pulses during maintenance treatment of childhood acute lymphoblastic leukemia on trial ALL-BFM 95.
Hinze L; Möricke A; Zimmermann M; Junk S; Cario G; Dagdan E; Kratz CP; Conter V; Schrappe M; Stanulla M
Leukemia; 2017 Aug; 31(8):1840-1842. PubMed ID: 28529312
[No Abstract] [Full Text] [Related]
17. Mercaptopurine metabolite levels are predictors of bone marrow toxicity following high-dose methotrexate therapy of childhood acute lymphoblastic leukaemia.
Vang SI; Schmiegelow K; Frandsen T; Rosthøj S; Nersting J
Cancer Chemother Pharmacol; 2015 May; 75(5):1089-93. PubMed ID: 25788208
[TBL] [Abstract][Full Text] [Related]
18. Pharmacogenetics predictive of response and toxicity in acute lymphoblastic leukemia therapy.
Mei L; Ontiveros EP; Griffiths EA; Thompson JE; Wang ES; Wetzler M
Blood Rev; 2015 Jul; 29(4):243-9. PubMed ID: 25614322
[TBL] [Abstract][Full Text] [Related]
19. The long-term results of childhood acute lymphoblastic leukemia at two centers from Turkey: 15 years of experience with the ALL-BFM 95 protocol.
Güneş AM; Oren H; Baytan B; Bengoa SY; Evim MS; Gözmen S; Tüfekçi O; Karapınar TH; Irken G
Ann Hematol; 2014 Oct; 93(10):1677-84. PubMed ID: 24863691
[TBL] [Abstract][Full Text] [Related]
20. Pharmacogenetics of childhood acute lymphoblastic leukemia.
Lopez-Lopez E; Gutierrez-Camino A; Bilbao-Aldaiturriaga N; Pombar-Gomez M; Martin-Guerrero I; Garcia-Orad A
Pharmacogenomics; 2014 Jul; 15(10):1383-98. PubMed ID: 25155938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
